Endometrial hyperplasia: The risk of progression to carcinoma in a series of 538 cases;Karzinomrisiko endometrialer hyperplasien: Eine kliniko-pathologische analyse von 538 fällen

Geburtshilfe und Frauenheilkunde

Volumn 61, Issue 7, 2001, Pages 501-506

  Horn, L C ^a   Schnurrbusch, U ^a   Bilek, K ^b   Einenkel, J ^b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GESTAGEN;

ARTICLE; CANCER GROWTH; CARCINOGENESIS; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ESTROGEN THERAPY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PREMENOPAUSE;

EID: 0034907820     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-15981     Document Type: Article

References (34)

1. Treatment of endometrial hyperplasia with gonadotropin-releasing hormone agonists: Pathological, clinical, morphometric and DNA-cytometric data
2. Assessment of the risk on endometrial cancer in hyperplasia by means of morphological and morphometrical features
3. Endometriumkarzinom
4. Wirkmechanismen ovarieller steroidhormone und antiöstrogene in der karzinogenese der mamma und des endometriums
5. Ovarielle steroidhormone und anti-östrogene: Risiken zu und prävention in der karzinogenese der mamma und des endometriums in der postmenopause
6. A multicentric European study testing the reproducibility of the WHO classification of endometrial hyperplasia with a proposal of a simplified Working Classification for biopsy and curettage specimens
7. Recent advances in the histopathology and molecular pathology of carcinoma of the endometrium
8. Oestrogens and proliferation of endometrial cells
9. Histopathologie und stadieneinteilung des endometriumkarzinoms inklusive seiner präkanzerosen
10. The use of luteinizing hormone releasing hormone agonists and antagonists in gynecologic cancer
11. Precursors of corpus carcinoma: I. Estrogens and adenomatous hyperplasia
12. Endometriale hyperplasien: Histologie, klassifikation, prognostische bedeutung und therapie
13. Präkanzeröse läsionen des endometriums: Aspekte der molekulare pathogenese und probleme der nomenklatur
14. Die genetischen grundlagen erblicher tumorkrankheiten beim Menschen
15. Endometrial carcinoma associated with hyperplasia
16. Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia and well differentiated carcinoma
17. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients
18. Analysis of p53 and K-ras mutations and microsatellite instability suggests distinct molecular genetic pathways in the pathogenesis of uterine endometrioid and serous carcinoma
19. Estrogen use and cancer risk: A review
20. The role of insulin and renin in the pathogenesis of hormone-dependent neoplasias. A insulin
21. Treatment of precursors of endometrial cancer
22. Über seltene gutartige und zweifelhafte epithelveränderungen der uterusschleimhaut im vergleich zu ihnen ähnlichen karzinomformen. 1. Endometritis, 2. Schleimhauthyperplasie, 3. Plattenepithelknötchen, 4. Polypen, 5. Papillome
23. Obesity and cancer risk: A Danish record-linkage study
24. Atypical endometrial hyperplasia simulating adenocarcinoma
25. Clinical response of abnormal endometrial growth to hormonal treatment
26. Screening asymptomatischer frauen auf endometriumkarzinom mit besonderer berücksichtigung des screenings unter tamoxifen-behandlung
27. Atypical endometrial hyperplasia treatment with progestogens and gonadotropin-releasing hormone analogues: Long-term follow up
28. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40
29. Relationship between carbohydrate metabolism and serum insulin-like growth factor system in postmenopausal women: Comparison of endometrial cancer patients with healthy controls
30. Adipositas und karzinomrisiko der frau
31. Zur prävalenz von hyperplastischen und neoplastischen veränderungen des endometriums bei postmenopausalen patientinnen mit mammakarzinom unter tamoxifentherapie
32. Obesity in Europe: Scaling and epidemic